sur INNATE PHARMA (EPA:IPH)
Innate Pharma to Present at Jefferies Global Healthcare Conference
Marseille-based Innate Pharma SA has announced its participation in the Jefferies Global Healthcare Conference 2025. The presentation is scheduled for November 17, 2025, from 2:30 to 2:55 PM GMT in London. Innate Pharma's executive team will engage in one-on-one meetings to discuss their current projects and advancements in immunotherapy for cancer treatment. A live webcast will be accessible through Innate Pharma's website.
Innate Pharma is known for developing antibody therapeutics focused on unmet medical needs. Their portfolio includes IPH4502, an ADC for solid tumors, lacutamab for T cell lymphomas, and monalizumab, developed with AstraZeneca for lung cancer. The company collaborates with major firms like Sanofi and AstraZeneca, emphasizing innovation in immuno-oncology.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de INNATE PHARMA